Introduction Across Europe, professionals are embracing a quiet revolution that challenges traditional workplace norms—microdosing psilocybin. Once confined to underground circles, this practice has gained legitimacy through scientific research and open-minded corporate cultures that value mental well-being and cognitive enhancement. Unlike high-dose psychedelic experiences, microdosing involves consuming sub-perceptual amounts of psilocybin—typically between 0.1 and 0.3 grams—to […]
Introduction The Netherlands has long been recognized as the psychedelic capital of Europe, a title rooted in its liberal drug policies, cultural openness, and pioneering approach to mental health therapies involving psilocybin and other plant-based entheogens. Unlike most of Europe, where psychedelic substances are heavily restricted, the Dutch government has taken a pragmatic and science-informed […]
Introduction: The Emergence of Psychedelic Therapy Across Europe Psychedelic therapy has rapidly evolved in Europe as a legitimate, research-driven approach to treating addiction, mood disorders, and cognitive impairments. Substances such as Ibogaine, psilocybin, and mescaline are increasingly integrated into structured clinical programs designed to address complex mental health challenges, including ADHD, depression, and sleep disorders. […]